Revolution Medicines, Inc. RVMD
Analyst Consensus
Price Objectif
Analyst historical
| Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
|---|---|---|---|---|---|
| Kelsey Goodwin | Piper Sandler | 36.56 $ | 75 $ | 38.44 % | 19/08/2025 |
| Robert Burns | H.C. Wainwright | 41.88 $ | 72 $ | 30.12 % | 14/05/2025 |
| Benjamin Burnett | Stifel Nicolaus | 33.62 $ | 64 $ | 30.38 % | 01/04/2025 |
| Eliana Merle | UBS | 44.33 $ | 71 $ | 26.67 % | 08/01/2025 |
| Joseph Catanzaro | Piper Sandler | 56.09 $ | 70 $ | 13.91 % | 07/11/2024 |
| Raghuram Selvaraju | H.C. Wainwright | 55.87 $ | 62 $ | 6.13 % | 04/11/2024 |
| Michael Schmidt | Guggenheim | 46.96 $ | 82 $ | 35.04 % | 28/10/2024 |
| Jay Olson | Oppenheimer | 46.83 $ | 60 $ | 13.17 % | 28/10/2024 |
| Jay Olson | Oppenheimer | 49.22 $ | 55 $ | 5.78 % | 15/10/2024 |
| Joseph Catanzaro | Piper Sandler | 44.24 $ | 57 $ | 12.76 % | 17/09/2024 |
| Ami Fadia | Needham | 42.73 $ | 61 $ | 18.27 % | 08/08/2024 |
| Robert Driscoll | Wedbush | 47.005 $ | 59 $ | 12.00 % | 15/07/2024 |
| Ben Burnett | Stifel Nicolaus | 35.83 $ | 43 $ | 7.17 % | 19/04/2024 |
| Ami Fadia | Needham | 37.41 $ | 46 $ | 8.59 % | 12/04/2024 |
| Jay Olson | Oppenheimer | 37.41 $ | 45 $ | 7.59 % | 12/04/2024 |
| Laura Prendergast | Raymond James | 32.99 $ | 48 $ | 15.01 % | 10/04/2024 |
| Dane Leone | Raymond James | 21.25 $ | 30 $ | 8.75 % | 16/11/2023 |